KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Cash & Current Investments (2017 - 2025)

Historic Cash & Current Investments for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $201.2 million.

  • Amneal Pharmaceuticals' Cash & Current Investments rose 17193.61% to $201.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $201.2 million, marking a year-over-year increase of 17193.61%. This contributed to the annual value of $110.6 million for FY2024, which is 2076.64% up from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' Cash & Current Investments stood at $201.2 million, which was up 17193.61% from $71.5 million recorded in Q2 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Cash & Current Investments peaked at $452.1 million during Q1 2021, and registered a low of $26.0 million during Q4 2022.
  • In the last 5 years, Amneal Pharmaceuticals' Cash & Current Investments had a median value of $92.0 million in 2022 and averaged $144.0 million.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Cash & Current Investments crashed by 8951.69% in 2022, and later skyrocketed by 25240.99% in 2023.
  • Amneal Pharmaceuticals' Cash & Current Investments (Quarter) stood at $247.8 million in 2021, then tumbled by 89.52% to $26.0 million in 2022, then skyrocketed by 252.41% to $91.5 million in 2023, then rose by 20.77% to $110.6 million in 2024, then surged by 82.04% to $201.2 million in 2025.
  • Its Cash & Current Investments stands at $201.2 million for Q3 2025, versus $71.5 million for Q2 2025 and $59.2 million for Q1 2025.